Has erlotinib been included in the scope of medical insurance reimbursement?

Erlotinib is a targeted drug commonly used to treat non-small cell lung cancer (NSCLC) and pancreatic cancer. It has been approved for marketing in China and has been included in the national medical insurance drug catalog, which means that its medication costs can be partially or fully reimbursed in accordance with medical insurance policies. According to the latest version of the "National Medical Insurance Drug Catalog" in 2023, erlotinib is included in the Category B drug catalog and is suitable for patients with advanced or metastatic non-small cell lung cancer who have positive EGFR gene sensitive mutations. Especially when used as a second-line or third-line drug after failure of first-line treatment, medical insurance coverage is more clear. Patients need to confirm their EGFR mutation status through genetic testing before using this drug to ensure the effectiveness of targeted therapy.

In terms of price, the original drug erlotinib was expensive when it was first launched. However, with the launch of generic drugs and the success of national medical insurance negotiations, its market price has dropped significantly. At present, there are many domestic generic versions available on the domestic market. The drug specifications are usually 150mg/tablet and 30 tablets per box. The price after medical insurance reimbursement varies depending on the region and reimbursement ratio, and is roughly between a few dozen yuan to six or seven hundred yuan per box. Patients can bring their doctor's prescription to a designated medical insurance pharmacy or hospital pharmacy to purchase. Some cities also support electronic prescriptions for online reimbursement for drug purchases, which greatly improves the accessibility of drugs.

It is worth noting that medical insurance reimbursement involves many factors such as whether the patient participates in urban and rural residents or employee medical insurance, whether the drug is purchased in the insured place, whether it meets the indications, and whether there is a limit on the reimbursement amount. Therefore, it is recommended that patients consult the medical insurance department or pharmacy department of their hospital in detail before purchasing drugs to confirm whether medical insurance covers all or part of the cost of the drug and the specific reimbursement process. For some patients whose medical insurance reimbursement coverage is limited or not covered, they can also pay attention to local medical insurance supplementary policies, new rural cooperative medical care policies or commercial insurance products to reasonably arrange their medication budget and reduce their financial burden.

Reference materials:https://en.wikipedia.org/wiki/Erlotinib